Sight Sciences Inc. Common Stock Q2 2025 Earnings Recap

Sight Sciences reported solid Q2 2025 results, achieving $19.6 million in revenue and raising its full-year revenue guidance to $72 million to $76 million due to robust growth in its Surgical Glaucoma segment.

Key Takeaways

• Surgical Glaucoma revenue increased by 12% sequentially, although it was down 5% year-over-year, highlighting resilience amidst evolving market conditions.
• The company achieved record high ordering accounts, up 6% sequentially, signaling effective client reengagement and new account acquisition.
• Strong early traction and positive surgeon feedback from the recently launched OMNIEdge technology are expected to bolster future utilization and growth.
• Maintained focus on operational excellence with high gross margins and diligent expense management, confirming commitment to long-term shareholder value.
• Continued efforts to secure positive reimbursement coverage for TearCare, aligning with broader market opportunities in minimally invasive glaucoma treatments.